Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine

[1]  J. Gartner,et al.  Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.

[2]  C. Dubay,et al.  Preliminary analysis of immune responses in patients enrolled in a Phase II trial of cyclophosphamide with allogenic dribble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIa or IIIb NSCLC , 2015, Journal of Immunotherapy for Cancer.

[3]  S. Gorski,et al.  Precision autophagy: Will the next wave of selective autophagy markers and specific autophagy inhibitors feed clinical pipelines? , 2015, Autophagy.

[4]  M. Büchler,et al.  Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice , 2015, International journal of cancer.

[5]  C. Dubay,et al.  Preliminary analysis of immune responses in patients enrolled in a Phase II trial of Cyclophosphamide with Allogenic DRibble Vaccine Alone (DPV-001) or with GM-CSF or Imiquimod for adjuvant treatment of Stage IIIA or IIIB NSCLC , 2014, Journal of Immunotherapy for Cancer.

[6]  B. Fox,et al.  DPV-001 an autophagosome-enriched cancer vaccine in phase II clinical trials contains 25 putative cancer antigens, DAMPS, HSPS and agonists for TLR 2, 3, 4, 7 and 9 , 2013, Journal of Immunotherapy for Cancer.

[7]  A. Thorburn,et al.  The vitamin E analogue α-TEA stimulates tumor autophagy and enhances antigen cross-presentation. , 2012, Cancer research.

[8]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy , 2011, Clinical Cancer Research.

[9]  J. Wolchok,et al.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab , 2011, Proceedings of the National Academy of Sciences.

[10]  B. Fox,et al.  Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism , 2011, Clinical Cancer Research.

[11]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[12]  Anna M. Keller,et al.  Identification of a dendritic cell receptor that couples sensing of necrosis to immunity , 2009, Nature.

[13]  W. Urba,et al.  Efficient cross-presentation depends on autophagy in tumor cells. , 2008, Cancer research.

[14]  B. Fox,et al.  Induction of Circulating Tumor-reactive CD8+ T Cells After Vaccination of Melanoma Patients With the gp100209-2M Peptide , 2007, Journal of immunotherapy.

[15]  Olivier Lantz,et al.  Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.

[16]  W. Alvord,et al.  gp100209–2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells , 2004, Clinical Cancer Research.

[17]  J. Yewdell,et al.  Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.

[18]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[19]  Y. Isaka,et al.  Chloroquine in cancer therapy: a double-edged sword of autophagy. , 2013, Cancer research.